Floatz logo

Irinotecan

Hormone-resistant Prostate Cancer

Roswell Park Cancer InstituteSmall moleculePhase 3Dormant
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Hormone-resistant Prostate Cancer cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 3BBB
PREDNISONE TABLETS
University of California, Davis
Phase 3BB
Abiraterone Acetate
Alliance for Clinical Trials in Oncology
Phase 3BB
Rebimastat
National Cancer Institute (NCI)
Phase 2B
Eloxatin
University of Southern California
Phase 2B

View all 27 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →